Yes .... Lately there is a trend to have shorter ADT treatments for this reason. PC patients fortunately live for many, many years, even decades and to get new data one has also to wait for many, many years to see the "end point" results.

I always thought that "PC Specific Mortality" should be the mayor factor in treatment decision, not overall survival. I always try to concentrate on those parameters and was surprised to see that actually PC SPECIFIC mortality gives somewhat different picture about certain treatments, actually more promising picture IMHO and that truly there IS such a thing as over-treatment and sometimes getting possibly one more year (15 instead of 14 for example ) perhaps is not so attractive if that one year is going to mean years of uncomfortable side effects.

It is all sooooo complicated and overwhelming and constantly changing but that is how it is - science and discoveries are evolving and that is good !